The past few days have been hard on many traders. We are all looking at a sea of red in our portfolios. This happens when you invest. Markets go up. Markets go down. But there are still some bright spots on the OTC Markets. 4 top penny stocks today are Artificial Intelligence Technology Solutions (OTCMKTS: AITX), Enzolytics (OTCMKTS: ENZC), MindMed (OTCMKTS: MMEDF), and HUMBL Inc (OTCMKTS: TSNPD).
WHAT’S AN INVESTOR TO DO?
First, it’s important to understand the 3 most important rules of investing.
- Buy low.
- Sell high.
- Don’t be afraid to take profits.
It has been an incredible run for OTC stock investors so far in 2021. We all have made a tremendous amount of money. Investors should have been periodically selling and booking gains.
If an investor has not been selling along the way, they got greedy. Plain and simple.
With social media, it’s easier now than ever to determine market sentiment. The bullish sentiment just got too extreme. Valuations got too far out of whack. For those that say valuation doesn’t matter, it does.
PLAN TO ACTION
There are two choices for investors right now because selling is not an option.
One, investors can do their homework and look for OTC stocks that haven’t run yet. This is what we do at Insider Financial. We scan through hundreds of OTC stocks each week looking for the best alerts for our subscribers.
We preach the key to trading OTC stocks is finding momentum BEFORE it happens and then be patient. Now, when we say that we find momentum BEFORE it happens, we are investors looking to position our subscribers BEFORE the move happens.
We got our subscribers in early on HUMBL, which you can read our first article here, and ALPP, which you can read about here. This is where the big money is made and why so many of our subscribers are sitting on gains of over 8113% in ALPP and over 17,400% in TSNP.
It’s also best to own a portfolio of quality OTC stocks. For some that can be as many as 10 to 20 or more OTC stocks.
We always alert our subscribers first before we publish for our regular readers. This is the value of having a subscription to Insider Financial, which you can sign up for here. We alert our subscribers with our best ideas before our regular readers.
The second move for OTC stock investors is to look for quality OTC stocks that are still showing relative strength. We are talking about OTC stocks that are holding up well in the sell-off. This indicates that there’s a strong shareholder base that is not pressured to sell.
Furthermore, these stocks are not correlated with the rest of the OTC Markets.
What do we mean by this?
Investors right now are chasing many of the same names. You talk to any OTC trader and most will tell you they are in ALPP, ABML, AABB, HCMC, etc.
This is why it’s so important to always be looking for new ideas and be diversified. A concentrated portfolio of too few names can be very, very painful in the short run and quite distressing for a new OTC investor.
YOU MUST LEARN TO EARN!
We try to help as much as we can, but in the end, it’s all up to you. You are running your own trading business.
Investing is not a team sport.
The purpose of what we do here at Insider Financial is not only to find winning alerts but also to teach. But we are just one resource. There are other resources as well.
For instance, if you want to day trade, we recommend the folks at True Trading Group, which you can check out their live streams here. They have a chat room as well as a ton of educational resources for their members.
The one negative about True Trading Group is that they don’t cover OTC stocks much. However, the good news is that we specialize in OTC stocks here at Insider Financial. In this article, we take a look at 4 top penny stocks today AITX, ENZC, MMEDF, and TSNPD find out what’s behind the move and our outlook for each.
Top Penny Stocks Today AITX
AITX is a top penny stock that we profiled back in December when it was under $.02 a share and which you can read here.
The latest news from the company is that its wholly-owned subsidiary Robotic Assistance Devices (RAD) received its highest dollar value order commitment to date, a nine-unit Wally HSO order from a Fortune 500 company with the ultimate end-user being a renowned Fortune 50 global company.
Seven of the nine orders are in hand with the last two additional orders expected last week. These orders are from the logistics client that placed two Wally HSO units in service near the end of 2020 bringing their Wally HSO count to eleven. This particular client has several additional RAD units deployed throughout the country with dozens of additional units under contemplation.
The company also stated that additional anticipated orders and dealer channel activity would be announced at a later date.
What attracted us to AITX was the announcement on December 15, AITX restructured over 85% of its convertible debentures into non-convertible notes and warrants. The remaining noteholders have not made any conversions in over two years and the company does not anticipate any further conversions prior to restructuring the remaining balance of the debentures.
AITX restructured a total of $7,141,110 of convertible debt into $7,141,110 of non-convertible promissory notes with a 36-month maturity and 12% annual compounded interest and 780M warrants with a 36-month maturity and $0.002 exercise price. The exercise price was calculated by taking the average closing price of the last ten trading days ended December 10 and adding an approximately 25% premium.
Moving forward AITX said that it will seek debt and low dilutive types of financing as it continues to grow and reach its objectives.
Top Penny Stocks Today ENZC
ENZC has been making big moves that have caught the attention of Jim Cramer.
First, Cathie Wood is a genius Second, her fund is uniquely not set up for the spike in rates,. Why no love for ENZC, which is the best drug company in the universe.
— Jim Cramer (@jimcramer) February 24, 2021
It’s taken Cramer some time to figure ENZC out, but Insider Financial subscribers have known about ENZC since October when the stock was just $.014 a share, and which you can read our initial coverage here.
The Audits of the Company’s current and prior year Financial Statements are in process and the application for OTCQB is being prepared for submission upon issuance of the Audited Statements. The Company plans to complete the two-year audit as quickly as possible but will file December 31, 2021, Annual Report Financial Statements pursuant to the OTC Markets Pink Basic Disclosure Guidelines. The Company anticipates filing the financial statements under the Basic Disclosure Guidelines for December 31, 2020, in the coming weeks before the filing deadline of March 31, 2021.
Last week, ENZC announced that it has identified eleven conserved, expectedly immutable sites (epitopes) on the Coronavirus against which it is producing targeted anti-SARS-CoV-2 monoclonal antibodies. Using computer analysis (Artificial Intelligence [AI]), the Company’s genetics and molecular biology data science team has now screened more than 50,512 Coronavirus isolates currently known and has identified conserved sites which expectedly are immutable. The 11 conserved sequences identified on the virus isolates curated have been identified on the basis that they are 98.71% to 99.29% conserved over the entirety of the 50,512 Coronavirus isolates analyzed.
The Company has always emphasized the need for therapeutics that target conserved and expectedly immutable virus sites – whether the therapeutics is a monoclonal antibody or a preventative vaccine. There is agreement among experts that multiple neutralizing antibodies are critical to the effective control of viruses such as the Coronavirus.
Recognizing this necessity, if a site is 99% conserved (exits in all 99% of the 50,512 Coronavirus isolates curated), then it can be expected that the next 50,512 variations will also contain the conserved sites. Targeting these conserved sites allows the production of a therapeutic that will not become ineffective due to mutation of the virus. In other words, even a “variant form of the virus” will expectedly contain the immutable targeted sites. Targeting those immutable sites avoids the ineffectiveness that is experienced when a therapeutics or vaccine targets a site that has mutated.
ENZC is also making progress in Bulgaria with its Planned Clinical Trials of Its Patented ITV-1 Anti-HIV. Its joint venture there has entered negotiations to engage Clinic Design to begin the clinical trials that may be required under EMA standards.
Bulgaria is a cheaper option for testing and as a member of the European Medicines Agency (EMA), Bulgaria is recognized under the Mutual Recognition Agreement (MRA) between the FDA and European Union for medicinal products for human use subject to limitations.
This allows drug inspectors to rely upon information from drug inspections conducted within countries recognized under the Treaty. By doing the testing in Bulgaria, it’s a backdoor and a faster pathway to FDA approval.
ENZC remains one PR away from new highs.
Top Penny Stocks Today MMEDF
We told our subscribers about MMEDF back in September, which you can read here. MMEDF is just another example of when we say find the momentum BEFORE it happens!!
MMEDF is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic-inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC.
The MindMed executive team brings extensive biopharmaceutical experience to the company’s groundbreaking approach to developing the next generation of psychedelic-inspired medicines and therapies.
MMEDF just acquired HealthMode, a digital medicine and therapeutics startup that uses Artificial Intelligence (AI)-enabled digital measurement to increase the precision and speed of clinical research and patient monitoring.
MindMed Co-Founder and CEO J.R. Rahn said: “The HealthMode acquisition marks the start of MindMed 2.0 as we seek to not only build a drug development company for psychedelic medicines, but also a comprehensive mental health technology platform to one day potentially launch these transformative medicines to patients in a scalable manner.”
The acquisition will help build a full-stack digital mental health platform for psychedelic medicines. Ex-Pfizer Digital Medicine Executive Dr. Daniel R. Karlin and former Google AI/ML industry veteran Bradford Cross have been added to the MindMed executive team.
Top Penny Stocks Today TSNPD
TSNPD is running after enacting a reverse split and the TSNP symbol getting the D added. TSNPD will become HMBL on March 26, 2021.
TSNPD just acquired Tickeri for $20 million in cash and stock. In the video above, we talk about why we like this acquisition and go into details about why HUMBL remains a top penny stock today.
Our subscribers have been in TSNPD since the beginning of November and have been richly rewarded as you can see from the chart below.
In our latest article, you can read why it’s best to ignore the shorts and buy the HUMBL dips, which you can read here.
These 4 OTC stocks are making moves despite the overall weakness in the markets. As we keep saying, there are always opportunities in the markets and it’s our job to find winning stocks. Huge gains can be made in such a short amount of time.
Our best advice in these tough times is to be patient and throw bids in below the market. Buying dips and selling rips as swing trades remains the best strategy in these markets.
It’s also important to look for OTC stocks that have yet to run. There are plenty of opportunities out there and we look at hundreds of OTC stocks each week trying to find the best alerts for our subscribers.
Remember, all it takes is one or two to become a winner and you’ve crushed the market indices for the year.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.